Core Viewpoint - Weikang Pharmaceutical (300878.SZ) has recently received a notice of acceptance for a supplementary application for its Jin Qian Cao capsules from the National Medical Products Administration, indicating progress in its product development and regulatory approval process [1] Group 1: Product Information - Jin Qian Cao capsules are designed to clear damp-heat, promote urination, reduce swelling, and are indicated for conditions such as heat stranguria, sand stranguria, painful urination, jaundice, carbuncles, and snake bites, as well as liver and gallbladder stones and urinary stones [1]

Core Viewpoint - Weikang Pharmaceutical (300878.SZ) has recently received the Acceptance Notice for the supplementary application of Jin Qian Cao capsules from the National Medical Products Administration, indicating progress in its product development and regulatory approval process [1] Group 1: Product Information - Jin Qian Cao capsules are indicated for clearing damp-heat, promoting urination, reducing swelling, and treating various conditions such as heat dysuria, sand dysuria, jaundice, carbuncles, snake bites, liver and gallbladder stones, and urinary tract stones [1]

Group 1 - The company, Weikang Pharmaceutical, has recently received a notice of acceptance for a supplementary application for Jin Qian Cao capsules from the National Medical Products Administration [1]

证券代码：300878 证券简称：维康药业 公告编号：2025-053 浙江维康药业股份有限公司 关于获得药品补充申请受理通知书的公告 受理号：CYZB2503241 根据《中华人民共和国行政许可法》第三十二条的规定，经审查，决定予以 受理。 二、金钱草胶囊的相关情况 金钱草胶囊，清利湿热，通淋，消肿。用于热淋，沙淋，尿涩作痛，黄疸尿 赤，痈肿疔疮，毒蛇咬伤，肝胆结石，尿路结石。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江维康药业股份有限公司（以下简称"公司"）于近日获得国家药品监督 管理局发出的金钱草胶囊的补充申请《受理通知书》。现将相关情况公告如下： 一、受理通知书主要内容 产品名称：金钱草胶囊 申请事项：境内生产药品补充申请 申请人：浙江维康药业股份有限公司 三、同类药品的情况 截至本公告披露日，经查询国家药品监督管理局网站，取得该品种的药品批 准文号的企业有：四川省通园制药集团有限公司、江西博士达药业有限责任公司。 四、对公司的影响及风险提示 上述药品补充申请获得受理通知书对公司近期业绩不会产生影响，后续能否 获得国家药品监督管理局批准尚存在 ...

证券代码：300878 证券简称：维康药业 公告编号：2025-052 浙江维康药业股份有限公司 | 上海浦东发展银行股份有限 公司丽水分行 | 39010078801500000923 | 营销网络中心建设项目建设 | 存续 | | --- | --- | --- | --- | | 中国工商银行股份有限公司 丽水经济开发区支行 | 1210206029100008883 | 医药大健康产业园一期项目 （中药饮片及中药提取、研发 | 本次注销 | | | | 中心、仓储中心） | | | 中国银行股份有限公司丽水 | 371478478159 | 补充营运资金项目 | 已注销 | | 市分行 | | | | | 中国农业银行股份有限公司 | 19855101040035208 | 超募资金 | 存续 | | 丽水莲都支行 | | | | 三、本次注销的部分募集资金专户情况 关于部分募集资金专户注销的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意浙江维康药业股份有限公司首次公开 发行股票注册的批复 ...

Core Viewpoint - The traditional Chinese medicine sector experienced a decline of 0.9% on December 29, with *ST Changyao leading the drop. The Shanghai Composite Index closed at 3965.28, up 0.04%, while the Shenzhen Component Index closed at 13537.1, down 0.49% [1]. Group 1: Stock Performance - The following stocks in the traditional Chinese medicine sector showed notable performance: - WoHua Pharmaceutical (002107) closed at 6.33, up 2.43% with a trading volume of 106,100 shares and a transaction value of 65.58 million yuan [1]. - Tianmu Pharmaceutical (600671) closed at 17.39, up 1.81% with a trading volume of 22,600 shares and a transaction value of 39.17 million yuan [1]. - Weikang Pharmaceutical (300878) closed at 25.75, up 0.66% with a trading volume of 20,500 shares and a transaction value of 53.04 million yuan [1]. - Tongrentang (600085) closed at 32.46, up 0.65% with a trading volume of 168,300 shares and a transaction value of 221 million yuan [1]. - Yunnan Baiyao (000538) closed at 56.69, down 0.02% with a trading volume of 61,100 shares and a transaction value of 346 million yuan [1]. Group 2: Capital Flow - The traditional Chinese medicine sector saw a net outflow of 689 million yuan from institutional investors, while retail investors contributed a net inflow of 462 million yuan [2]. - Notable capital flows for specific stocks include: - Tongrentang (600085) had a net inflow of 28.03 million yuan from institutional investors, but a net outflow of 19.15 million yuan from retail investors [3]. - Wanbangde (002082) experienced a net inflow of 12.49 million yuan from institutional investors, with a net outflow of 9.44 million yuan from retail investors [3]. - Ma Yinglong (600993) had a net inflow of 5.11 million yuan from institutional investors, while retail investors saw a net inflow of 3.19 million yuan [3].

从资金流向上来看，当日中药板块主力资金净流出3857.06万元，游资资金净流出9028.32万元，散户资 金净流入1.29亿元。中药板块个股资金流向见下表： 证券之星消息，12月19日中药板块较上一交易日上涨0.69%，维康药业领涨。当日上证指数报收于 3890.45，上涨0.36%。深证成指报收于13140.22，上涨0.66%。中药板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 ...

Core Viewpoint - The A-share market shows positive momentum with the Shanghai Composite Index closing at 3890.45 points, above the half-year line, reflecting a gain of 0.36% and a total trading volume of 1.748742 trillion yuan [1] Group 1: Market Performance - The Shanghai Composite Index closed at 3890.45 points, above the half-year line, with a gain of 0.36% [1] - Total trading volume in the A-share market reached 1.748742 trillion yuan [1] Group 2: Stocks Breaking Half-Year Line - A total of 266 A-shares have surpassed the half-year line, indicating strong market interest [1] - Notable stocks with significant deviation rates include: - GQY Vision (10.23%) - Hongwei Technology (9.84%) - Zhongwang Fabric (8.75%) [1] Group 3: Detailed Stock Data - GQY Vision: Today's price increased by 11.23% with a turnover rate of 13.78%, latest price at 7.23 yuan [1] - Hongwei Technology: Today's price increased by 12.30% with a turnover rate of 17.12%, latest price at 27.49 yuan [1] - Zhongwang Fabric: Today's price increased by 9.98% with a turnover rate of 1.78%, latest price at 25.78 yuan [1]

Group 1 - The Shanghai Composite Index closed at 3887.81 points, above the six-month moving average, with a gain of 0.30% [1] - The total trading volume of A-shares reached 1,390.087 billion yuan [1] - A total of 249 A-shares have surpassed the six-month moving average, with notable stocks including GQY Vision, Hongwei Technology, and Zhongwang Fabric, showing significant deviation rates of 12.05%, 9.88%, and 8.75% respectively [1] Group 2 - GQY Vision (300076) had a daily increase of 13.08% with a turnover rate of 10.52%, and its latest price was 7.35 yuan, showing a deviation rate of 12.05% [1] - Hongwei Technology (688711) increased by 12.34% with a turnover rate of 15.68%, latest price at 27.50 yuan, and a deviation rate of 9.88% [1] - Zhongwang Fabric (605003) rose by 9.98% with a turnover rate of 1.76%, latest price at 25.78 yuan, and a deviation rate of 8.75% [1]

证券日报网讯 12月15日晚间，维康药业发布公告称，公司于近日取得浙江省药品监督管理局换发的 《药品生产许可证》，换发后的《药品生产许可证》有效期至2030年12月11日。 （文章来源：证券日报） ...